Goldstein Robert B, Storch Eric A, Lehmkuhl Heather, Geffken Gary R, Goodman Wayne K, Murphy Tanya K
Depress Anxiety. 2009;26(1):E23-5. doi: 10.1002/da.20448.
There are no reports of a child taking a selective serotonin reuptake inhibitor and an atypical anti-psychotic being successfully tapered from these medications after completion of cognitive-behavioral therapy (CBT) for obsessive-compulsive disorder. With this in mind, we report the case of an 8.5-year-old male who was taking risperidone 0.5 mg bid, sertraline 100 mg, and atomoxetine 25 mg at presentation. After a successful course of CBT, we describe how medications were systematically withdrawn. Implications of this case on practice parameters (e.g., CBT may be an effective augmenting agent for those non-responsive to initial pharmacological treatments) are highlighted.
尚无关于患有强迫症的儿童在完成认知行为疗法（CBT）后成功减停选择性5-羟色胺再摄取抑制剂和非典型抗精神病药物的报道。考虑到这一点，我们报告一例8.5岁男性病例，该患儿就诊时正在服用利培酮0.5毫克，每日两次，舍曲林100毫克，以及托莫西汀25毫克。在成功完成CBT疗程后，我们描述了如何系统性地减停药物。强调了该病例对实践参数的影响（例如，CBT可能是对初始药物治疗无反应者的一种有效增效剂）。
